Inhaled drug delivery for tuberculosis therapy.

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) infects one-third of the global population, with new infections occurring rapidly.
• Emerging drug-resistant Mycobacterium tuberculosis strains and a lack of effective anti-TB drugs threaten TB containment.
• Sub-therapeutic antibiotic levels in poorly vascularized lung lesions contribute to drug resistance.

Purpose of the Study:

• To explore the potential of inhaled anti-TB therapy to overcome challenges in treating sequestered mycobacteria.
• To investigate methods for achieving therapeutic drug concentrations within lung lesions.

Main Methods:

• Discusses the rationale for pulmonary drug administration to target lung lesions.
• Highlights the potential of inhaled therapies to supplement conventional oral and parenteral treatments.

Main Results:

• Inhaled drug delivery allows for higher concentrations near lung lesions compared to systemic routes.
• Pulmonary administration can potentially achieve therapeutic levels within sequestered bacterial populations.

Conclusions:

• Inhaled anti-TB therapy offers a promising strategy to enhance treatment efficacy in lung lesions.
• This approach may be crucial in combating drug-resistant tuberculosis and preventing its spread.